In a series of 7 webinar this programme will develop a full picture of the C. difficile infection (CDI) reaching from the importance of a healthy gut microbiota, to its detection and testing methods to current and future therapeutic approaches.

The first 2-3 years of life are crucial for shaping childhood health. Amid others, the importance of early-life gut microbiota in infant’s development and later human health has been long speculated. In particular, bifidobacteria are playing an essential role in infant’s gut microbiota and immune system maturation that supports its probiotic use in that age span.

Clostridioides difficile infection is the most frequent cause of antibiotic-associated diarrhea in the hospital setting that has increased in severity. This article looks at the risk factors for developing C. difficile-associated disease, the spectrum of manifestations and the impact of the COVID-19 pandemic on the occurrence of C. difficile infection.

Bioaccumulation: a new perspective in the drug-bug story

24 Jan 2022

by Konstantina Zafeiropoulou

In Western world, the incidence of autoimmune and autoinflammatory diseases has been significantly increasing and also the use of non-antibiotic drugs for their treatment. Scientists at EMBL and Cambridge University elucidate how common drugs accumulate in gut bacteria and potentially reduce medication’s effectiveness.

Despite the global focus on COVID-19, 2021 was also a productive year in gut microbiome research. In this “2021 Year at a glance” report, discover emerging trends in postbiotics, the role of beneficial microbes in dietary guidelines, diet-related tools for shaping the gut microbiome and the potential role of newly identified probiotics in obesity and functional dyspepsia.

As we look back, we can certainly say that 2021 has been a productive year for gut microbiome research. In this last post of the year, we bring you key articles from our blog and studies on major advances in the role of the gut microbiome in maintaining health and helping to manage gut and immune-related diseases. We will also look at the therapeutic potential of probiotics, prebiotics and postbiotics for your clinical practice.